- Home
- CAAS vs PLX Comparison
CAAS vs PLX Comparison
Compare CAAS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAS
- PLX
- Stock Information
- Founded
- CAAS N/A
- PLX 1993
- Country
- CAAS China
- PLX United States
- Employees
- CAAS N/A
- PLX N/A
- Industry
- CAAS Auto Parts:O.E.M.
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAAS Consumer Discretionary
- PLX Health Care
- Exchange
- CAAS Nasdaq
- PLX Nasdaq
- Market Cap
- CAAS 125.2M
- PLX 122.6M
- IPO Year
- CAAS N/A
- PLX 1998
- Fundamental
- Price
- CAAS $4.21
- PLX $1.40
- Analyst Decision
- CAAS
- PLX Strong Buy
- Analyst Count
- CAAS 0
- PLX 1
- Target Price
- CAAS N/A
- PLX $15.00
- AVG Volume (30 Days)
- CAAS 18.7K
- PLX 640.7K
- Earning Date
- CAAS 08-12-2025
- PLX 08-13-2025
- Dividend Yield
- CAAS 18.96%
- PLX N/A
- EPS Growth
- CAAS N/A
- PLX N/A
- EPS
- CAAS 0.96
- PLX 0.05
- Revenue
- CAAS $678,635,000.00
- PLX $59,764,000.00
- Revenue This Year
- CAAS N/A
- PLX $65.02
- Revenue Next Year
- CAAS N/A
- PLX $57.34
- P/E Ratio
- CAAS $4.42
- PLX $28.96
- Revenue Growth
- CAAS 18.33
- PLX 0.18
- 52 Week Low
- CAAS $3.34
- PLX $0.82
- 52 Week High
- CAAS $5.37
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CAAS 51.23
- PLX 30.38
- Support Level
- CAAS $4.23
- PLX $1.52
- Resistance Level
- CAAS $4.37
- PLX $1.65
- Average True Range (ATR)
- CAAS 0.13
- PLX 0.08
- MACD
- CAAS -0.00
- PLX 0.02
- Stochastic Oscillator
- CAAS 36.36
- PLX 17.19
About CAAS China Automotive Systems Inc.
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.